Ferring Pharmaceuticals, Inc. Release: FIRMAGON┬« (degarelix) Demonstrates Non-inferiority to goserelin with bicalutamide in Reducing Prostate Volume in Prostate Cancer Patients while Providing Better Relief from Lower Urinary Tract Symptoms  
2/28/2012 7:02:47 AM

PARIS--(BUSINESS WIRE)--Two new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that FIRMAGON® (degarelix), a gonadotropin-releasing hormone (GnRH) receptor blocker, was similar to the combination of goserelin (a luteinizing-hormone-releasing hormone (LHRH) agonist) plus bicalutamide at reducing total prostate volume in men with advanced hormone-dependent prostate cancer, and offered better control of lower urinary tract symptoms (LUTS).1,2 LUTS can include frequency, urgency and hesitancy in urination and have a major negative impact on quality of life3,4 for men with prostate cancer.